Posted by Michael Wonder on 16 Dec 2021
Verrica Pharmaceuticals announces acceptance by FDA of NDA resubmission for VP-102 for the treatment of molluscum contagiosum
15 December 2021 - Verrica Pharmaceuticals today announced that the U.S. FDA acknowledged that Verrica’s resubmitted new drug application for VP-102 for the treatment of molluscum contagiosum was complete and assigned a Prescription Drug User Fee Act goal date of 24 May 2022.
Verrica’s lead product candidate, VP-102, is a proprietary drug-device combination product that contains a GMP controlled formulation of cantharidin (0.7% w/v) delivered via a single-use applicator that allows for precise topical dosing and targeted administration.
